Versicor was a recent IPO. From their web site...
Versicor is focusing on antiinfective products that have competitive advantages over existing products, such as greater potency, improved effectiveness against resistant strains and reduced toxicity. Because the development process for antiinfectives is relatively efficient and well-defined, we believe the costs and time required to bring new products to market can be significantly less than other major therapeutic categories. Our product candidates target disease indications that represent substantial markets where there is significant demand for new therapies.
Our approach to product development and marketing is two-fold: Our primary strategy is to develop proprietary injectable antibiotics and antifungals for the hospital market, which accounted for $6.5 billion in worldwide sales in 1998. We expect to market these to hospitals in North America through our own direct sales force.
Our secondary strategy is to collaborate with major pharmaceutical companies to develop orally administered antibiotics and antifungals. Through these collaborations, we intend to leverage our technology platform to discover and supply lead compounds while our partners conduct pre-clinical, clinical development, marketing and sales activities to transform the compounds into pharmaceutical products. We expect to receive research funding, milestone payments, royalty fees and equity investments from our collaborative partners if the products are commercialized.
versicor.com |
